全文获取类型
收费全文 | 58291篇 |
免费 | 3799篇 |
国内免费 | 1358篇 |
专业分类
耳鼻咽喉 | 549篇 |
儿科学 | 1217篇 |
妇产科学 | 584篇 |
基础医学 | 4364篇 |
口腔科学 | 520篇 |
临床医学 | 8270篇 |
内科学 | 11189篇 |
皮肤病学 | 287篇 |
神经病学 | 3136篇 |
特种医学 | 2502篇 |
外国民族医学 | 2篇 |
外科学 | 6339篇 |
综合类 | 9092篇 |
现状与发展 | 3篇 |
预防医学 | 4142篇 |
眼科学 | 2791篇 |
药学 | 6172篇 |
38篇 | |
中国医学 | 1578篇 |
肿瘤学 | 673篇 |
出版年
2023年 | 875篇 |
2022年 | 1200篇 |
2021年 | 2081篇 |
2020年 | 2189篇 |
2019年 | 1855篇 |
2018年 | 1946篇 |
2017年 | 1909篇 |
2016年 | 1933篇 |
2015年 | 1860篇 |
2014年 | 3991篇 |
2013年 | 4262篇 |
2012年 | 3502篇 |
2011年 | 3746篇 |
2010年 | 2851篇 |
2009年 | 2700篇 |
2008年 | 2747篇 |
2007年 | 2733篇 |
2006年 | 2439篇 |
2005年 | 1992篇 |
2004年 | 1761篇 |
2003年 | 1436篇 |
2002年 | 1274篇 |
2001年 | 1169篇 |
2000年 | 986篇 |
1999年 | 894篇 |
1998年 | 757篇 |
1997年 | 763篇 |
1996年 | 655篇 |
1995年 | 700篇 |
1994年 | 609篇 |
1993年 | 524篇 |
1992年 | 539篇 |
1991年 | 453篇 |
1990年 | 403篇 |
1989年 | 370篇 |
1988年 | 374篇 |
1987年 | 339篇 |
1986年 | 301篇 |
1985年 | 348篇 |
1984年 | 346篇 |
1983年 | 213篇 |
1982年 | 278篇 |
1981年 | 229篇 |
1980年 | 201篇 |
1979年 | 172篇 |
1978年 | 154篇 |
1977年 | 93篇 |
1976年 | 82篇 |
1975年 | 57篇 |
1974年 | 40篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
《Journal of vascular and interventional radiology : JVIR》2022,33(8):895-902.e4
PurposeTo study, from a U.S. payer’s perspective, the economic consequences of drug-coated balloon (DCB) versus standard percutaneous transluminal angioplasty (PTA) use for the treatment of stenotic lesions in dysfunctional hemodialysis arteriovenous fistulae.Materials and MethodsCost differences between DCBs and PTA at year 1 and beyond were calculated via 2 methods. The first approach used the mean absolute number of trial-observed access circuit reinterventions through 12 months (0.65 ± 1.05 vs 1.05 ± 1.18 events per patient for DCBs and PTA, respectively) and projected treatment outcomes to 3 years. The second approach was based on the trial-observed access circuit primary patency rates at 12 months (53.8% vs 32.4%) and calculated the cost difference on the basis of previously published Medicare cost for patients who maintained or did not maintain primary patency. Assumptions regarding DCB device prices were tested in sensitivity analyses, and the numbers needed to treat were calculated.ResultsUsing the absolute number of access circuit reinterventions approach, the DCB strategy resulted in an estimated per-patient savings of $1,632 at 1 year and $4,263 at 3 years before considering the DCB device cost. The access circuit primary patency approach was associated with a per-patient cost savings of $2,152 at 1 year and $3,894 at 2.5 years of follow-up. At the theoretical DCB device reimbursement of $1,800, savings were $1,680 and $2,049 at 2.5 and 3 years, respectively. The one-year NNT of DCB compared to PTA was 2.48.ConclusionsEndovascular therapy for arteriovenous access stenosis with the IN.PACT AV DCB can be expected to be cost-saving if longer follow-up data confirm its clinical effectiveness. 相似文献
3.
4.
《Journal of vascular and interventional radiology : JVIR》2022,33(4):399-407
PurposeTo evaluate the midterm outcomes of percutaneous transluminal renal angioplasty (PTRA) for pediatric renovascular hypertension (RVH).Materials and MethodsThe clinical data of patients who underwent PTRA for RVH in the authors’ hospital from 2012 to 2019 were retrospectively analyzed. Postprocedural blood pressure, glomerular filtration rate (GFR) of the affected kidney, restenosis, and complications were closely monitored.ResultsPTRA was performed in a total of 30 children (20 boys and 10 girls), with a mean age of 7.3 years ± 0.7 (range, 40 days to 13.9 years) and a mean weight of 25.0 kg ± 2.3 (range, 3.4–53 kg). The median follow-up period was 26.5 months (range, 1 month to 7.5 years). Technical success was achieved in 26 (86.7%) of the 30 patients. Restenosis developed in 3 patients (10.0%). Only 1 patient underwent stent implantation, and the stent fractured 8 months later, requiring further intervention. There were no other complications. In terms of clinical benefit of blood pressure control after the initial PTRA procedure, 15 patients (50%) were cured and 7 patients (23.3%) showed improvement. There was no significant difference in the etiology, lesion location, and lesion length between patients with clinical benefit and failure (P = .06, P = .202, and P = .06, respectively). GFR of the affected kidney was significantly improved from 19.9 mL/min ± 11.2 to 38.1 mL/min ± 11.9 at the 6-month follow-up after PTRA (P < .001).ConclusionsThe overall results of PTRA for pediatric RVH caused by different etiologies are promising. PTRA not only provided a clinical benefit of blood pressure control in 73.3% of the patients but also significantly improved the function of the affected kidney. 相似文献
5.
目的 分析双水平气道正压双水平气道正压通气(bi-level positive airway pressure,BiPAP)对阻塞性睡眠呼吸暂停低通气综合征(obstructive sleep apnea hypopnea syndrome,OSAHS)患者血管内皮功能及预后的影响。
方法 将100例OSAHS患者纳入研究,随机分为观察及对照组,各50例。观察组行BiPAP
,对照组行常规治疗,比较两组多导睡眠监测(polysomnography,PSG)检查指标(低通气指数、呼吸暂停指数、呼吸暂停及低通气时间、90%以下血氧饱和度次数、90%以下血氧饱和度时间)、心肺功能[脑钠肽(brainnatriureticpeptide,BNP)、右心室Tei指数、左心室Tei指数、一秒用力呼气容积占用力肺活量的百分比(forced expiratory volume in one second/forced vital capacity,FEV1/FVC)、一秒用力呼气容积占预计值的百分比(FEV1占预计值%)]、血管内皮功能[内皮素1(endothelin-1,ET-1)、一氧化氮(nitric oxide,NO)、凝血酶Ⅲ(antithrombin Ⅲ,AT-Ⅲ)]及生活质量。
结果 观察组低通气指数、呼吸暂停指数、呼吸暂停及低通气时间、90%以下血氧饱和度次数及时间指标均显著低于对照组(P<0.05)。观察组治疗后BNP以及Tei指数显著低于治疗前及对照组治疗后,FEV1/FVC、FEV1占预计值%显著高于治疗前及对照组治疗后(P<0.05)。观察组治疗后ET-1、AT-Ⅲ低于治疗前及对照组治疗后,NO高于治疗前及对照组治疗后(P<0.05)。观察组治疗后生活质量各项目评分高于对照组(P<0.05)。
结论 BiPAP治疗能够改善OSAHS患者的预后情况及血管内皮功能,效果确切。 相似文献
6.
采用Mimics对心脏进行三维重构,用3-matic进行模型优化以及模型误差分析,对左心室室壁运动做速度分布假设,基于UDF宏文件对左心室室壁运动编写程序,将血液视为非牛顿流体,采用动网格技术研究不同血压对左心室血液流动的影响。模拟发现当左心室收缩时,压力梯度明显,内部压力减小。当左心室舒张时,内部压力逐渐增高。二尖瓣口处的速率先增大后减小。血压升高,左心室内剪切应力持续增大,极易破坏红细胞结构,产生溶血现象,导致心脏功能紊乱。 相似文献
7.
8.
9.
10.